Takeda Signs Agreement With Galaxy Biotech for HuL2G7

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 8
Volume 15
Issue 8

Takeda Pharmaceutical has signed an exclusive licensing agreement with Galaxy Biotech (Mountain View, California) to develop, manufacture, and market HuL2G7, a recombinant humanized anti-hepatocyte growth factor (anti-HGF) monoclonal antibody developed by Galaxy Biotech. HGF is believed to mediate proliferation, metastasis, antiapoptosis, and neoangiogenesis of many types of tumors. In animal models, treatment of intracranial glioma xenografts with HuL2G7 induced substantial tumor regression and prolonged survival (Clin Cancer Res 12:1292-1298, 2006).

TOKYO, Japan—Takeda Pharmaceutical has signed an exclusive licensing agreement with Galaxy Biotech (Mountain View, California) to develop, manufacture, and market HuL2G7, a recombinant humanized anti-hepatocyte growth factor (anti-HGF) monoclonal antibody developed by Galaxy Biotech. HGF is believed to mediate proliferation, metastasis, antiapoptosis, and neoangiogenesis of many types of tumors. In animal models, treatment of intracranial glioma xenografts with HuL2G7 induced substantial tumor regression and prolonged survival (Clin Cancer Res 12:1292-1298, 2006).

Articles in this issue
Younger Age at Brain Tumor Diagnosis Portends Poor Emotional Outcome
Higher Responses in Metastatic Colon Ca When Cetuximab Added to Chemo
Triple Targeted Therapy Is Tested in Pts With Solid Tumors
FDA Approves Three-Drug Combination Tablet for HIV-1
Side Effects Persist 16 Years After Prostate Ca Brachytherapy
No Significant QOL Differences for Raloxifene and Tamoxifen
Amrubicin Appears Promising in Small-Cell Lung Cancer
R-MP Active in Older Pts With Newly Diagnosed Myeloma
Sunitinib and Sorafenib Active in Phase II Advanced NSCLC Trials
Takeda Signs Agreement With Galaxy Biotech for HuL2G7
Experimental Regimens Fail to Boost Pancreatic Survival
Adding Bortezomib Ups Dual Transplant Results in Myeloma
Demand Spurs Efforts to Improve Recruitment, Retention
Why Has Mortality Related to Pancreatectomy Declined?
Phase III Trial Finds XP as Efficacious as EP as First-Line Therapy for Metastatic Breast Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Related Content
Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma

Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma

Ariana Pelosci
May 30th 2025
Article

Andrew Brenner, MD, PhD, discussed rhenium obisbemeda and results from the ReSPECT-GBM trial for patients with glioblastoma.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology

Shwetal Mehta, PhD
January 27th 2025
Podcast

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Maximizing Safe Resection in High-Grade Gliomas

Maximizing Safe Resection in High-Grade Gliomas

Ariana Pelosci
May 13th 2025
Article

Jennifer Moliterno, MD, FAANS, discusses current neurosurgical strategies for newly diagnosed high-grade gliomas.

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Forming Connections and Making a Difference in the Brain Cancer Field

Yoshie Umemura, MD
October 7th 2024
Podcast

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Advancing the Glioma Treatment Paradigm With Immunotherapy and Novel Strategies

Advancing the Glioma Treatment Paradigm With Immunotherapy and Novel Strategies

Ariana Pelosci
May 12th 2025
Article

Nicholas Blondin, MD, provides an in-depth discussion on the evolving role of immunotherapy in the treatment of primary and metastatic brain tumors.

“The findings show that access to clinical trials alone is insufficient to overcome the inferior survival outcomes experienced by Black and Hispanic children with cancer,” according to lead study author Puja Umaretiya, MD, MS.

Data Show Racial/Ethnic Disparities in Pediatric Brain Cancer Survival

Russ Conroy
May 5th 2025
Article

Clinical trial access alone appears to be insufficient in overcoming the worse survival outcomes observed in Black and Hispanic pediatric populations.